Kidney Cancer Principles and Practice
Kidney Cancer: Principles and Practice is a comprehensive and interdisciplinary textbook that encompasses all clinically relevant aspects of the disease. This new edition has been extensively updated and includes brand new material covering the most recen
- PDF / 12,367,823 Bytes
- 400 Pages / 504.63 x 737.01 pts Page_size
- 1 Downloads / 261 Views
Kidney Cancer Principles and Practice Second Edition
123
Kidney Cancer
Primo N. Lara Jr. • Eric Jonasch Editors
Kidney Cancer Principles and Practice Second Edition
Editors Primo N. Lara Jr. Department of Internal Medicine Division of Hematology-Oncology University of California Davis School of Medicine UC Davis Comprehensive Cancer Center
Sacramento, CA USA
Eric Jonasch Department of Genitourinary Medical Oncology University of Texas MD Anderson Cancer Center Houston, TX USA
ISBN 978-3-319-17902-5 ISBN 978-3-319-17903-2 DOI 10.1007/978-3-319-17903-2
(eBook)
Library of Congress Control Number: 2015942674 Springer Cham Heidelberg New York Dordrecht London © Springer International Publishing 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)
Preface
Important discoveries in the genetics and molecular biology of kidney cancer (or renal cell carcinoma) have driven the development of multiple new therapeutic approaches for patients with advanced disease. The characterization of the VHL gene as a regulator of angiogenesis has made renal cell carcinoma a paradigmatic disease for treatment with vascular endothelial growth factor pathway inhibitors. These agents are capable of inducing tumor shrinkage and of prolonging progression-free intervals in a significant number of patients. Inhibitors of the mTOR pathway have also demonstrated efficacy in individuals with this disease. In the United States (as of 2015), there are eight Food and Drug Administration-approved agents available for individuals with advanced renal cell carcinoma, including five antiangiogenic agents, two mTOR inhibitors, and one cytokine. However, it is clear that despite this relative wealth of new drugs, the vast majority of patients with advanced stage disease are not being cured. Much progress still needs to be made in our understanding of renal cell carcino
Data Loading...
